Approxima Selected for the MedTech Innovator 2026 Program
Aegis Capital portfolio company, Approxima, has been selected for this year's edition of the MedTech Innovator program, currently the largest accelerator for medical technology companies in the world. This milestone is further underscored by the fact that out of 1,835 applications worldwide, the organizers selected only 65 startups for the 2026 cohort. While the geographical structure of this elite group is heavily dominated by US-based companies (nearly 60%), approximately 30% of the selected entities originate from Europe.
The primary technological sectors represented in the 2026 cohort include diagnostics, gastroenterology, neurotech, and cardiology—the specific segment where the European company is building its position as an innovation leader.
Innovation in Structural Cardiology
Approxima develops technology focusing on a novel approach to treating tricuspid regurgitation (TR). The company is designing a minimally invasive, transcatheter right ventricular reshaping system aimed at restoring proper valve function. A detailed analysis of the medical challenge associated with this condition, the historical therapeutic barriers, and the mechanism of action of the developed solution can be found in the dedicated article on the Aegis Capital website:
- Article link: A disease of the aging heart that has remained without effective treatment for decades
The scale of the clinical challenge addressed by Approxima aligns with the mission of the global accelerator, which focuses on selecting projects with the highest potential impact on modern healthcare.
The MedTech Innovator Ecosystem and Achievements
MedTech Innovator has been operating for 13 years, establishing a global ecosystem to support breakthrough medical innovations. The program's prestige and the track record of its selection process are demonstrated by the historical performance metrics of its alumni:
- 838 program alumni,
- ➡️Over 500 FDA clearances and approvals secured by portfolio companies,
- ➡️Over $11.4 billion in follow-on funding raised by participants,
- ➡️92% company survival rate (entities that remain active or have been acquired),
- ➡️Approximately 40% of all capital transactions in the medtech sector in 2025 went to companies corporate-linked to the program.
This established market positioning translates directly into tangible benefits for the participants, opening up unique commercialization and financing pathways.
Acceleration Scope and Global Horizons
Participation in the program grants the selected companies direct access to an international network of corporate and institutional partners. This closed ecosystem includes global medtech and healthcare corporations (such as Johnson & Johnson, Edwards Lifesciences, and Dexcom), leading medical providers (including Mayo Clinic and UCLA Health), as well as hundreds of specialized institutional investors (Venture Capital funds) and angel investors.
A critical component of the acceleration process is exposure at key market events. The program includes pitching sessions at major global industry conferences, such as:
- 🔸JP Morgan HealthcareJP Morgan HealthcareJP Morgan Healthcare (San Francisco, USA),
- 🔸The MedTech Strategist (Dublin, Ireland),
- 🔸Device Talks (Boston, USA),
- 🔸ApacMed’s MedTech Forum (Singapore).
-
The full official press release from the organizer, including the complete list of the selected companies and details regarding the launch of the MTI Index platform, is available on the official website:
